Christopher B. Ford

3.2k total citations · 1 hit paper
42 papers, 2.1k citations indexed

About

Christopher B. Ford is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Christopher B. Ford has authored 42 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 24 papers in Molecular Biology and 19 papers in Epidemiology. Recurrent topics in Christopher B. Ford's work include Clostridium difficile and Clostridium perfringens research (23 papers), Gut microbiota and health (21 papers) and Mycobacterium research and diagnosis (9 papers). Christopher B. Ford is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (23 papers), Gut microbiota and health (21 papers) and Mycobacterium research and diagnosis (9 papers). Christopher B. Ford collaborates with scholars based in United States, United Kingdom and Canada. Christopher B. Ford's co-authors include Sarah M. Fortune, JoAnne L. Flynn, Philana Ling Lin, Rupal Shah, Thomas R. Ioerger, James C. Sacchettini, Marc Lipsitch, Richa Gawande, Amy Myers and M. Teresa Coleman and has published in prestigious journals such as Nature Medicine, Nature Communications and Nature Genetics.

In The Last Decade

Christopher B. Ford

38 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing

2013 374 citations Philana Ling Lin, Christopher B. Ford et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher B. Ford United States	14	1.3k	1.0k	810	413	193	42	2.1k
Kathryn Winglee United States	18	774 0.6×	553 0.5×	960 1.2×	267 0.6×	222 1.2×	36	1.9k
Janet F. Staab United States	26	1.7k 1.3×	1.1k 1.1×	840 1.0×	67 0.2×	176 0.9×	33	2.6k
Bryan P. Hurley United States	25	512 0.4×	213 0.2×	491 0.6×	182 0.4×	544 2.8×	57	1.9k
Bret R. Sellman United States	26	714 0.5×	327 0.3×	1.2k 1.5×	124 0.3×	389 2.0×	41	2.2k
Andreas Kupz Australia	20	752 0.6×	630 0.6×	456 0.6×	150 0.4×	661 3.4×	53	1.8k
Alfredo Menéndez Canada	24	303 0.2×	258 0.2×	958 1.2×	124 0.3×	396 2.1×	48	1.8k
Gudrun Holland Germany	21	621 0.5×	484 0.5×	646 0.8×	76 0.2×	165 0.9×	49	1.6k
H C Krivan United States	20	955 0.7×	416 0.4×	848 1.0×	209 0.5×	509 2.6×	26	2.3k
Julie McAuley Australia	24	582 0.4×	1.7k 1.6×	1.1k 1.3×	255 0.6×	1.1k 5.7×	40	3.1k

Countries citing papers authored by Christopher B. Ford

Since Specialization

Citations

This map shows the geographic impact of Christopher B. Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher B. Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher B. Ford more than expected).

Fields of papers citing papers by Christopher B. Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher B. Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher B. Ford. The network helps show where Christopher B. Ford may publish in the future.

Co-authorship network of co-authors of Christopher B. Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher B. Ford. A scholar is included among the top collaborators of Christopher B. Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher B. Ford. Christopher B. Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bryant, Jessica A., Timothy J. Straub, Darrell S. Pardi, et al.. (2025). Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection. The Journal of Infectious Diseases. 232(5). e733–e740.

Peled, Jonathan U., Marcel R.M. van den Brink, Doris M. Ponce, et al.. (2023). Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT). Blood. 142(Supplement 1). 2198–2198.

Gonzales-Luna, Anne J, et al.. (2023). 653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI). Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Straub, Timothy J., Mary‐Jane Lombardo, Jessica A. Bryant, et al.. (2023). Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With RecurrentClostridioides difficileInfection. Clinical Infectious Diseases. 78(4). 833–841. 7 indexed citations

DesJardins, Christopher, Jessica A. Bryant, Emily Walsh, et al.. (2022). Su1606: ENGRAFTMENT OF INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-109 IS DURABLE THROUGH 24 WEEKS IN A RANDOMIZED TRIAL (ECOSPOR III) FOR THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology. 162(7). S–650. 2 indexed citations

Vulić, Marin, et al.. (2021). 130. Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases. 8(Supplement_1). S79–S80. 1 indexed citations

Ford, Christopher B., et al.. (2021). A CASE OF GIANT LEFT ATRIAL APPENDAGE WITH ATRIAL FIBRILLATION MASQUERADING AS SYMPTOMATIC PERICARDIAL EFFUSION. Journal of the American College of Cardiology. 77(18). 2689–2689. 1 indexed citations

Ford, Christopher B., et al.. (2021). SMART WARS - COMPARISON OF THE APPLE WATCH SERIES 4 AND KARDIABAND SMART WATCH TECHNOLOGY FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION. Journal of the American College of Cardiology. 77(18). 3226–3226.

Moura, Inês B., Jessica A. Bryant, Emma Clark, et al.. (2021). Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. npj Biofilms and Microbiomes. 7(1). 16–16. 47 indexed citations

10.

Gopalakrishnan, Vancheswaran, Bryan J. Weiner, Christopher B. Ford, et al.. (2020). Intervention strategies for microbial therapeutics in cancer immunotherapy. Immuno-Oncology Technology. 6. 9–17. 11 indexed citations

11.

Yu, Elaine W, Liu Gao, Michael C. Cheney, et al.. (2020). OR26-06 Fecal Microbiota Transplantation Trial for the Improvement of Metabolism (FMT-TRIM): A Randomized Double-Blind Placebo-Controlled Pilot Trial. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

12.

Muñoz, José F., Toni Delorey, Christopher B. Ford, et al.. (2019). Coordinated host-pathogen transcriptional dynamics revealed using sorted subpopulations and single macrophages infected with Candida albicans. Nature Communications. 10(1). 1607–1607. 56 indexed citations

13.

Farrer, Rhys A., Christopher B. Ford, Johanna Rhodes, et al.. (2018). Transcriptional Heterogeneity of Cryptococcus gattii VGII Compared with Non-VGII Lineages Underpins Key Pathogenicity Pathways. mSphere. 3(5). 12 indexed citations

14.

Ford, Christopher B., Jason Funt, Darren Abbey, et al.. (2015). The evolution of drug resistance in clinical isolates of Candida albicans. eLife. 4. e00662–e00662. 245 indexed citations

15.

Rock, Jeremy M., Michael R. Chase, Christopher B. Ford, et al.. (2015). DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader. Nature Genetics. 47(6). 677–681. 52 indexed citations

16.

Cilfone, Nicholas A., Christopher B. Ford, Simeone Marino, et al.. (2014). Computational Modeling Predicts IL-10 Control of Lesion Sterilization by Balancing Early Host Immunity–Mediated Antimicrobial Responses with Caseation during Mycobacterium tuberculosis Infection. The Journal of Immunology. 194(2). 664–677. 60 indexed citations

17.

Lin, Philana Ling, Christopher B. Ford, M. Teresa Coleman, et al.. (2013). Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nature Medicine. 20(1). 75–79. 374 indexed citations breakdown →

18.

Ford, Christopher B., Rupal Shah, Sébastien Gagneux, et al.. (2013). Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nature Genetics. 45(7). 784–790. 313 indexed citations

19.

Liong, Monty, Anh Hoang, Jaehoon Chung, et al.. (2013). Magnetic barcode assay for genetic detection of pathogens. Nature Communications. 4(1). 1752–1752. 144 indexed citations

20.

Ford, Christopher B., et al.. (2013). The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosisfrom cynomolgus macaque infection. BMC Genomics. 14(1). 145–145. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact